Wall Street brokerages forecast that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will post $1.05 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest EPS estimate is $0.94 and the highest is $1.16. Enanta Pharmaceuticals reported earnings per share of ($0.09) in the same quarter last year, which indicates a positive year-over-year growth rate of 1,266.7%. The business is scheduled to announce its next quarterly earnings report on Monday, November 20th.
On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $0.02 per share for the current year, with EPS estimates ranging from $0.01 to $0.03. For the next financial year, analysts anticipate that the business will post earnings of ($0.10) per share, with EPS estimates ranging from ($0.42) to $0.21. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The firm had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. Enanta Pharmaceuticals’s quarterly revenue was down 46.3% on a year-over-year basis.
Several equities analysts have recently issued reports on the company. Robert W. Baird lifted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. BidaskClub cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a report on Tuesday, July 11th. Finally, ValuEngine upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $33.00.
Several institutional investors have recently modified their holdings of the company. GAM Holding AG bought a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $108,000. Mason Street Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares during the last quarter. Institutional investors and hedge funds own 65.95% of the company’s stock.
WARNING: This piece was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://baseballnewssource.com/markets/zacks-brokerages-anticipate-enanta-pharmaceuticals-inc-nasdaqenta-to-post-1-05-earnings-per-share/1408762.html.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.90% on Friday, reaching $39.23. The company had a trading volume of 279,701 shares. Enanta Pharmaceuticals has a 12 month low of $21.00 and a 12 month high of $41.20. The company’s market capitalization is $748.63 million. The stock has a 50 day moving average price of $36.29 and a 200-day moving average price of $32.18.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.